Osteologix osteoporosis drug posts positive study results

NBS-101 is being studied as an improved tablet formulation of strontium, which was recently approved in Europe, in the form of strontium ranelate, and launched in several European countries.

The objective of this NBS-101 human clinical trial was to establish the dose required to deliver the same blood levels of strontium as the recently approved European product.

NBS-101 showed bioequivalence to strontium ranelate at a dose substantially lower than the strontium ranelate product, which should allow for the administration of NBS-101 as a once a day oral tablet.

Using specific biomarkers for bone turnover, the study also provided clinical evidence that NBS-101 had the dual effect of reducing degradation of bone while having a positive effect on bone formation. There were no treatment related side effects in the study subjects who were given NBS-101.

“The results of this clinical trial were very encouraging. Because of its unique mechanism of action, and the lower bioequivalent dosing levels found in this study, we anticipate that NBS-101 could lead to an effective, safer and more convenient drug to administer for Osteoporosis,” said Charles Casamento, CEO and president of Osteologix.